Rapamycin · dosing
Rapamycin dosage for longevity: where the numbers actually come from
The most common rapamycin dosage for longevity is 6 mg once a week, yet the only placebo trial of weekly dosing ran 48 weeks (per the 2025 PEARL trial) and tested 5 mg and 10 mg. No trial found the 6 mg figure, no regulator approved it, and here is how it became the default anyway.
Is there an established rapamycin dosage for longevity?
No: the longest placebo-controlled human trial of weekly dosing lasted 48 weeks (per the 2025 PEARL trial), far short of any lifespan endpoint. A dose is normally set against a measurable benefit, and for longevity there is no agreed biomarker to titrate against, only a tolerability ceiling and convention.
Every dose figure you will read is either an animal number, a transplant number, or a description of what people are already doing. None of them is an answer to the question being asked.
What rapamycin dose extended lifespan in mice?
Strong human evidence The 2009 result used food at 14 parts per million (about 2.24 mg/kg daily) from 600 days of age.[1] A later dose and timing review found that mid-life initiation extends mouse lifespan by roughly 9 to 14 percent depending on the regimen (per the 2014 Kaeberlein review).[2] [3]
Why mouse doses do not translate
Two things follow:
- The animal evidence is for continuous exposure, not the weekly pulses humans actually use.
- Converting milligrams per kilogram in a mouse into milligrams in a person needs metabolic scaling assumptions never validated for this drug.
Reviews of animal regimens note intermittent schedules as the ones that avoided adverse metabolic effects, which is where the human intermittent logic originates.[4] The one randomized test of intermittent dosing in a non-laboratory mammal is running in pet dogs, in the TRIAD arm of the Dog Aging Project.
Where did the 6 mg weekly dose come from?
From observed practice, not a trial: a 2024 systematic review of human use found the most common off-label regimens were 6 mg weekly and 6 mg every 14 days.[5] A 2025 GeroScience analysis of real-world cohorts reached the same conclusion independently: 6 mg per week was by far the most commonly administered longevity dose.[6]
Note what those two papers are describing. They are documenting behavior, not validating it. The figure spread through clinician networks, podcasts and forums, and its main qualification is that a lot of people use it.
There's nothing saying that 6 mg is the best dose.
Show the numbers as a table
| Measure | Value |
|---|---|
| Most common off-label | 6 mg/week |
| PEARL low arm | 5 mg/week |
| PEARL high arm | 10 mg/week |
Does the same weekly dose give everyone the same blood level?
No: the same 2025 cohort work measured blood levels rather than just doses, and found wide variation between individuals taking identical amounts.[7] Absorption, CYP3A4 activity and food all move the number.
So two people on 6 mg weekly may not be running the same experiment at all. The transplant world solved this decades ago by dosing to a measured blood concentration rather than to a milligram figure. Longevity use cannot copy that solution, because no target concentration for the intended effect has ever been defined.
What doses have human trials tested?
Early / mixed evidence The PEARL trial compared 5 mg and 10 mg weekly against placebo over 48 weeks in healthy older adults, reporting tolerability, lean tissue and pain changes.[8] It was a safety and feasibility study. It did not test a dose range against an efficacy endpoint, because there is no agreed efficacy endpoint to test against.
A recent review of off-label use in healthy adults reached the conclusion that the clinical picture remains insufficient to guide practice.[9] That assessment applies to the dose question with particular force.
Why is rapamycin taken weekly instead of daily?
To hit mTORC1 briefly and spare mTORC2, with six days of clearance between doses. Sustained exposure also reaches mTORC2, and mTORC2 inhibition is where much of the insulin resistance and metabolic disturbance seen in transplant patients is thought to originate. A weekly dose is an attempt to separate the two.
Plausible, not yet shown in people
The argument is plausible and not proven in humans. It is also the reason the transplant side effect list may not transfer, which we go through in detail in our page on what changes at different doses. The best hint that exposure need not be continuous comes from mice given the drug for one short course and then stopped.
Only 12 weeks of rapamycin was enough to increase remaining life expectancy by more than 60%.
How do prescribers adjust a rapamycin dose in practice?
By tolerability rather than a measured target: off-label prescribers setting a rapamycin dosage for longevity generally start low, extend the interval, and adjust on side effects, since identical doses produce widely varying blood levels.[7]
How to take rapamycin for longevity under supervision
Mouth ulcers are the practical signal that exposure has risen, and the response is a smaller dose or a longer gap. Monitoring covers silent effects: lipids, blood counts, glucose or HbA1c, liver and kidney function.
Grapefruit is avoided outright rather than adjusted for, because CYP3A4 inhibition raises the effective exposure by an unpredictable amount. The same applies to several common medicines, which is why a prescriber needs the full list before any figure is chosen. Access and prescribing routes are covered in our page on cost and access.
Show the numbers as a table
| When | Event | Detail |
|---|---|---|
| 2009 | Mouse lifespan study | Started at 600 days |
| 2014 | Dose-timing review | Mid-life start works |
| 2024 | Off-label review | 6 mg weekly most common |
| 2025 | PEARL trial | 5 and 10 mg, 48 weeks |
| 2025 | Real-world cohort | Blood levels vary |
How should you read a rapamycin dose figure?
Ask which question the number was built to answer, because 4 different settings publish rapamycin doses for 4 different purposes:
- Transplant medicine: a blood concentration for immunosuppression.
- Oncology: the maximum the patient can tolerate.
- Mouse studies: continuous exposure in an animal with a much faster metabolism.
- Longevity protocols: what people do, and nothing more.
None of those is a rapamycin dosage for longevity in the sense the question implies, because that number does not exist yet. Anyone quoting one with confidence is quoting a convention. Our main evidence guide sets out what a trial would have to show before a real number could be written down.
Frequently asked questions
What is the rapamycin dosage for longevity?
There is no established one. The dose that appears most often in surveys of people already taking it is 6 mg once a week, and that number reflects convergent practice rather than any trial that compared doses. No regulator has approved a longevity dose and no trial has identified an optimal one.
How much rapamycin do people actually take?
A systematic review of off-label use found the most common regimens were 6 mg once a week and 6 mg every 14 days (per the 2024 systematic review), with a minority reporting much higher amounts. A 2025 real-world cohort analysis reached the same conclusion: 6 mg weekly dominates.
What would a trial need to measure before a dose could be recommended?
An agreed marker of slowed aging, or a hard outcome such as disease incidence, compared across at least two doses. No trial has done this, which is why every figure in circulation describes practice rather than proof.
Does blood level testing help with dosing?
It reveals how variable the picture is. A 2025 cohort study found that identical weekly doses produced widely different blood concentrations between individuals, which means milligrams are a poor proxy for exposure. What nobody knows is which blood level, if any, corresponds to a longevity benefit.
How long has anyone taken weekly rapamycin under trial conditions?
48 weeks is the longest placebo-controlled record, set by the 2025 PEARL trial. Everything beyond that is self-reported off-label use with no control group, so nobody can say what several years of weekly dosing does.
Why can't a mouse dose simply be scaled up for a person?
Because the mice ate the drug continuously, while people take weekly pulses, and converting milligrams per kilogram across species relies on metabolic scaling assumptions never validated for rapamycin. The mouse figure describes a different exposure pattern, not a smaller version of a human dose.
Is more rapamycin better?
There is no evidence for that and reason to think the opposite. Higher and more continuous exposure is exactly what produces the transplant side effect profile, and the animal dose-response is not simply linear. The people taking 20 mg or more are running an experiment on themselves with no supporting data.
How do clinicians decide where to start?
In practice, low and slow: a small starting amount, a long interval, and adjustment based on tolerability rather than any measured endpoint. That is a reasonable way to manage side effects. It is not a way to find an effective dose, because the effective dose has never been defined.
Should the dose be based on body weight?
The animal data are expressed per kilogram, and some clinicians scale accordingly. Human off-label practice mostly does not, which is one of several inconsistencies between the animal evidence people cite and the human protocols they follow.
Does grapefruit change the dose?
Effectively yes, and unpredictably. Grapefruit inhibits CYP3A4, the enzyme that clears the drug, so it raises blood concentration by an amount nobody can estimate in advance. This is why it is avoided rather than accounted for.
How long should someone stay on it?
Unknown. Every off-label protocol in circulation is open-ended, and no trial has run long enough to say whether a benefit accumulates, plateaus or reverses. The animal work suggests that starting in mid-life is sufficient, which at least argues against the idea that earlier is obviously better.
Is there a standard cycling protocol?
No. Some people take breaks of a few weeks or months, usually reasoning about immune function or wound healing around surgery or illness. None of these schedules has been tested against continuous weekly dosing.
What monitoring goes with any dose?
A lipid panel, complete blood count, fasting glucose or HbA1c, and liver and kidney function, taken before starting and repeated periodically. These catch the effects that produce no symptoms, which are the ones self-directed use misses entirely.
Why do the published figures disagree with each other?
Because they answer different questions: transplant doses target a blood concentration. Oncology doses target the maximum tolerated ceiling. Longevity doses target nothing measurable, so they converge on convention instead, which is how 6 mg weekly became a standard without ever being tested as one.
References
8 sources, all link-checked; oldest check
- Targeting aging with rapamycin and its derivatives in humans: a systematic review. Lee DJW et al. The Lancet Healthy Longevity 2024.Systematic review, cited 189 times.Publisher blocks automated checks · last tried Sep 15, 2026
- The bioavailability and blood levels of low-dose rapamycin for longevity in real-world cohorts of normative aging individuals. Harinath G et al. GeroScience 2025 (cited 11).6 mg per week was by far the most commonly administered longevity dose, with wide inter-individual variation in resulting blood levels.Verified Sep 15, 2026
- Rapamycin and aging: when, for how long, and how much?. Kaeberlein M. Journal of Genetics and Genomics 2014 (cited 62).Reviews the dose-response and timing data behind mouse lifespan extension, including 14 ppm from 600 days of age.Verified Sep 15, 2026
- Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Moel M et al. Aging (Albany NY) 2025;17(4):908–936.48-week RCT, 5/10 mg weekly; safe, no visceral-fat change; authors employed by AgelessRx; note conflict.Verified Sep 15, 2026
- Rapamycin for longevity: the pros, the cons, and future perspectives. Roark KM, Iffland PH. Frontiers in Aging 2025;6:1628187.Peer-reviewed review, cited 31 times.Verified Sep 15, 2026
- Impact of rapamycin on longevity: updated insights. Sanati M et al. Archives of Medical Science 2024 (cited 4).Review of animal dosing regimens, with intermittent administration the most common schedule that avoided adverse metabolic effects.Verified Sep 15, 2026
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Harrison DE et al. Nature 2009;460:392–395.9–14% mouse lifespan extension started mid-life.Verified Sep 15, 2026
- What is the clinical evidence to support off-label rapamycin therapy in healthy adults?. Hands SL, Lustgarten MS, Frame AA, Rosen CJ. Aging (Albany NY) 2025.Publisher blocks automated checks · last tried Sep 15, 2026
Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.
Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.
Own a longevity or health brand?
Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.